News

BIO: debating value in Chicago
Enlarge image

BusinessEU

BIO: debating value in Chicago

25.04.2013 - At the BIO International convention in Chicago, analysts have reported strong performance from the global biotech sector.

They pointed out that there is an urgent need for the industry to demonstrate value of products under development. For 2012, Ernst & Young’s industry report “Beyond borders” reports an increase in revenues by 8% to US$ 89.8bn, with the net income of US$5.2 bn, representing a record high. In Europe, revenues of public biotechs grew 8% to US$ 20.4bn. However, R&D expense decreased by 1 %, which is regarded as an indication that the firms remain in a cost-cutting mode. 

A new survey amongst small and mid-size companies has revealed an “implementation gap” when it comes to gathering evidence to demonstrate the value of products at early stages of development. “Biotech companies can no longer afford to pursue an R&D strategy that only focuses on whether or not their drug works”, said Gautam Jaggi from the Ernst &Young Global Life Sciences Center. Strategic investors and pharma alliance partners would now consider such data to be key drivers of their product and company valuations. “Companies cannot afford not to rethink their R&D approaches and to invest in addressing questions of value”, he said. 

In his talk, Steven Burrill presented similar view. The life science industry insider said in his “supersession”, that value of products is not a constant. “Instead, companies will need to be prepared to prove the value of their products in a world where value is transient, value is payer dependent and value is geographically different“, he said. And, as pressures on pricing intensify, companies will need to be creative in forging new ways to capture value. “Value, like beauty,”  Burrill said, “is in the eye of the beholder.” Companies should have that in mind very early in development.  Celebrating its 20th birthday, BIO International Convention was held in Chicago this year. The most important event for the global biotech industry has attracted over 2000 exhibitors this year, and will see more than 25.000 partnering meetings. 

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/bio-debating-value-in-chicago.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2296.2%
  • TRANSGENE (F)5.08 EUR77.0%
  • BIOTECH PHARMACON (N)12.60 NOK33.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.90 EUR-42.5%
  • BIONOR PHARMA (N)1.28 NOK-37.6%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 30.08.2015